We are live on ! Find out more
RCKT icon

Rocket Pharmaceuticals
RCKT

164 hedge funds and large institutions have $1.52B invested in Rocket Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 61 increasing their positions, 54 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

341% more call options, than puts

Call options by funds: $4.54M | Put options by funds: $1.03M

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

13% more capital invested

Capital invested by funds: $1.34B → $1.52B (+$177M)

13% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 54

6% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 17

1% more funds holding

Funds holding: 163 → 164 (+1)

3.73% less ownership

Funds ownership: 98.63% → 94.9% (-3.7%)

Holders
164
Holders Change
+1
Holders Change %
+0.61%
% of All Funds
2.57%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
18
Increased
61
Reduced
54
Closed
17
Calls
$4.54M
Puts
$1.03M
Net Calls
+$3.51M
Net Calls Change
+$371K

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$20.9M
2
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$8.48M
3
PA
Perceptive Advisors
New York
+$6.07M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$5.09M
5
PHS
PFM Health Sciences
California
+$4.82M

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$19.4M
2
State Street
State Street
Massachusetts
-$17M
3
LGM
Logos Global Management
California
-$13.1M
4
BlackRock
BlackRock
New York
-$6.69M
5
WP
Woodline Partners
California
-$5.59M
Name Holding Trade Value Shares
Change 		Change in
Stake
CUAMC
151
China Universal Asset Management Company
China
$20.9K -$424 -21 -2%
N
152
Natixis
France
$13.1K -$687 -34 -5%
S
153
SignatureFD
Georgia
$9.91K +$1.66K +82 +20%
HNB
154
Huntington National Bank
Ohio
$9.54K +$9.7K +480 New
WAM
155
Wolverine Asset Management
Illinois
$7.93K – – –
Daiwa Securities Group
156
Daiwa Securities Group
Japan
$6K – – –
QCG
157
Quadrant Capital Group
Ohio
$2.07K – – –
LC
158
Lindbrook Capital
California
$1.75K – – –
FHA
159
First Horizon Advisors
Tennessee
$1.03K – – –
MFG
160
Mendota Financial Group
Wisconsin
$895 +$404 +20 +80%
GI
161
Gradient Investments
Minnesota
$676 +$687 +34 New
IA
162
IFP Advisors
Florida
$497 – – –
NFSG
163
Newbridge Financial Services Group
Florida
$358 – – –
RCM
164
RA Capital Management
Massachusetts
– -$19.4M -1,131,775 Closed
WP
165
Woodline Partners
California
– -$5.59M -326,605 Closed
JFG
166
Jefferies Financial Group
New York
– -$4.03M -235,316 Closed
AA
167
ALPS Advisors
Colorado
– -$895K -52,273 Closed
Vontobel Holding
168
Vontobel Holding
Switzerland
– -$853K -49,799 Closed
JF
169
Jump Financial
Illinois
– -$758K -44,278 Closed
CAM
170
ClariVest Asset Management
California
– -$457K -26,702 Closed
HIS
171
Harvest Investment Services
Illinois
– -$457K -26,684 Closed
GC
172
Guggenheim Capital
Illinois
– -$201K -11,757 Closed
SG Americas Securities
173
SG Americas Securities
New York
– -$199K -11,612 Closed
DFCM
174
Dark Forest Capital Management
Puerto Rico
– -$82.1K -4,790 Closed
Simplex Trading
175
Simplex Trading
Illinois
– -$68.4K -3,385 Closed
4 5 6
7
8

RCKT Hedge Fund Activity: Q2 2023 in Review

164 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2023, worth a combined $1.52B — up 13% from $1.34B a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new RCKT positions and 17 closed out — a net gain of 1 holder — while 61 added to existing stakes and 54 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $20.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $19.4M sold.

  • 164 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2023, up from 163 in Q1 2023.
  • Funds reported $1.52B of Rocket Pharmaceuticals stock for Q2 2023, up 13% quarter-over-quarter.
  • 18 funds opened new Rocket Pharmaceuticals positions in Q2 2023 and 17 closed out, a net change of +1 holder.
  • The largest Rocket Pharmaceuticals buyer in Q2 2023 was Wellington Management Group, an estimated $20.9M added.
  • The largest Rocket Pharmaceuticals seller in Q2 2023 was RA Capital Management, an estimated $19.4M sold.

Based on aggregated 13F filings for Q2 2023.